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A B S T R A C T
Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic driver event in non-
small cell lung cancer (NSCLC). Classical activating mutations (exon 19 deletions and the L858R point mutation)
comprise the vast majority of EGFRmutations and are well defined as strong predictors for good clinical response
to EGFR tyrosine kinase inhibitors (EGFRi). However, low frequency mutations including point mutations, de-
letions, insertions and duplications occur within exons 18–25 of the EGFR gene in NSCLC and are associated with
poorer responses to EGFRi. Despite an increased uptake of more sensitive detection methods to identify rare
EGFR mutations in patients, our understanding of the biology of these rare EGFR mutations is poor compared to
classical mutations. In particular, clinical data focused on these mutations is lacking due to their rarity and
challenges in trial recruitment, resulting in an absence of effective treatment strategies for many low frequency
EGFR mutations. In this review, we describe the structural and mechanistic features of rare EGFR mutations in
NSCLC and discuss the preclinical and clinical evidence for EGFRi response for individual rare EGFR mutations.
We also discuss EGFRi sensitivity for complex EGFR mutations, and conclude by offering a perspective on the
outstanding questions and future steps required to make advances in the treatment of NSCLC patients that
harbour rare EGFR mutations.
1. Introduction
Activating mutations in the epidermal growth factor receptor
(EGFR) gene occur in 10–20% of Caucasian and at least 50% of Asian
non-small cell lung cancer (NSCLC) patients [1–4]. Two mutations,
deletions in exon 19 and the single amino acid substitution L858R in
exon 21, often referred to as “classical” EGFR mutations, together ac-
count for ˜85% of observed EGFR mutations in NSCLC (Fig. 1) and
confer sensitivity to EGFR tyrosine kinase inhibitors (EGFRi) [5–7].
Rare mutations account for the remaining ˜15% of EGFR mutations in
NSCLC and include point mutations, deletions and insertions within
exons 18–25 of the EGFR gene (Figs. 1 and 2) [8]. Despite being low
frequency mutations, given the high prevalence of lung cancer overall,
it is estimated that over 30,000 NSCLC patient new diagnoses per year
will harbour rare EGFR mutations. Therefore, it is crucial to understand
the biology of rare EGFR mutations and to assess the effectiveness of
current treatment options. One obstacle to understanding the differ-
ences in biology of rare EGFR mutations compared to classical EGFR
mutations is the lack of patient-derived NSCLC cell line models that
harbour endogenous rare EGFR mutations. Many preclinical studies
thus rely on exogenous expression of rare EGFR mutants in model cell
lines such as the mouse pro-B cell line Ba/F3 and mouse fibroblast cell
line NIH-3T3. Despite these limitations, structural and preclinical data
have been used to predict the efficacy of different EGFRi for specific
rare EGFR mutations. However, there are very few clinical trials that
systematically and robustly evaluate the efficacy of EGFRi in NSCLC
patients that harbour rare EGFR mutations. Due to the paucity of clin-
ical data, the field is largely reliant on pooled post-hoc analyses of
clinical trials and case series to evaluate EGFRi response in this het-
erogeneous group of patients. For example, in 2018 the FDA approved
the second-generation EGFRi afatinib for treatment of S768I, L861Q
and G719X rare EGFR point mutations based on evidence from pooled
analysis of three clinical trials, LUX-Lung 2, LUX-Lung 3 and LUX-Lung
6 [9,10]. In the following sections, we describe the structural features of
rare EGFR mutations and elaborate on the preclinical and clinical evi-
dence for EGFRi response for patients that harbour such rare EGFR
mutations.
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2. Classical EGFR mutations
2.1. Structural and mechanistic features
The kinase domain of EGFR has 2 lobes, the N-lobe and the C-lobe,
that are separated by the ATP binding cleft. The N-lobe of the EGFR
kinase domain is mainly formed of β-strands and the regulatory αC-
helix, whereas the larger C-lobe is mainly α-helical and contains the
activation loop (A-loop). The inactive state of wild-type (WT) EGFR is
characterized by an outward rotation of the αC-helix that is stabilized
by a helical turn within the N-terminal portion of the A-loop (Fig. 3)
[11]. This conformation prevents the catalytically important salt-bridge
interaction between K745 and E762 and is often referred to as the “Src/
CDK2-like inactive” conformation due to its similarity to the inactive
conformations of Src and CDK2 [12]. K745 and E762 are located in the
N-lobe, with E762 positioned on the αC-helix. Together they bind and
orientate ATP by forming interactions with the α and β phosphate of
ATP respectively. The N-lobe also contains the glycine-rich phosphate
binding loop (P-loop) while the C-lobe comprises the DFG motif, the
catalytic loop, and the catalytic base.
Structural studies have shown that L858R and exon 19 deletions
(Ex19Del) destabilize the inactive conformation of the receptor, leading
increased receptor dimerization and activity compared to WT [11,13,14].
L858 lies within the helical turn of the activation loop and forms crucial
hydrophobic interactions with residues in the N-lobe when the receptor is
in the inactive conformation (Fig. 3). Owing to arginine’s much larger
side chain compared to leucine, the L858R substitution is incompatible
with the inactive conformation and therefore “locks” the kinase domain
in a constitutively active conformation. When in the active conformation,
the positively charged L858R is surrounded by a cluster of negatively
charged residues (E758, D855, and D837) that further stabilize this
configuration [12]. Ex19Del is also thought to destabilize the inactive
conformation through shortening the β3-αC loop that prevents the out-
ward rotation of the αC-helix (Fig. 3) [12,14].
Fig. 1. Pie chart showing the frequencies of EGFR mutations in NSCLC. Data was acquired from COSMIC databases. Data was filtered to contain only mutations
from adenocarcinoma. The common resistance mutations T790M and C797S were filtered out.
Fig. 2. Lollipop plot showing the position of EGFR mutations and structural features of EGFR. Orange boxes indicate point mutations, blue boxes indicate
insertion/deletion mutations.
Fig. 3. Cartoon showing the structure of the
EGFR kinase domain in the active and in-
active conformation. In the left panel the in-
active conformation is shown, and important
residues and structural features are labelled. In
the right panel the active conformation is
shown, and the approximate location of muta-
tions reported in NSCLC are labelled. Dashed
lines indicate salt-bridge interactions.
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2.2. Clinical response to EGFRi
First-generation EGFRi are ATP-competitive, reversible inhibitors
that preferentially bind to classical EGFR mutant receptors over WT
EGFR. L858R and Ex19Del mutant EGFR have a lower affinity for ATP
compared to WT EGFR, enabling first-generation EGFRi to outcompete
ATP and thus prevent receptor activation [11,15]. This differential af-
finity gives the inhibitors a large therapeutic window, with gefitinib
showing a ˜100 fold increase in potency against L858R compared to
WT. This increased potency translates into a 72% response rate (RR)
and nearly 10 months median progression-free survival (PFS) in pa-
tients with these mutations when treated with first-generation EGFRi
[11,16–18]. The most common resistance mechanism to first-genera-
tion EGFRi is the gatekeeper mutation T790M, occurring in ˜60% of
patients who acquired resistance to first-generation EGFRi [19]. This
mutation increases the ATP affinity of the receptor and sterically hin-
ders drug binding, preventing first-generation EGFRi from out-
competing ATP and resulting in activation of the receptor despite EGFRi
treatment [20]. Second-generation EGFRi were developed to address
the issue of acquired resistance to first-generation EGFRi. This class of
compounds binds irreversibly to EGFR at the C797 residue by covalent
adduct formation. After forming a covalent, irreversible complex the
competitive equilibrium with ATP is lost, overcoming drug resistance
caused by the T790M mutation which possesses similar ATP affinity to
WT EGFR. Despite promising preclinical results, second-generation
EGFRi largely failed in clinical trials evaluating patients with T790M-
mediated first-generation EGFRi resistance [21–24]. This failure is due
to poor selectivity of the drug for L858R/T790M or Ex19Del/T790M
EGFR mutants over WT EGFR, leading to dose-limiting toxicities which
limits the clinical efficacy of these drugs in this setting [25–27]. Third-
generation EGFRi also bind irreversibly to EGFR by covalent adduct
formation. However, in contrast to second-generation EGFRi, third-
generation EGFRi show greater selectivity for EGFR T790M mutations
over WT EGFR compared to second-generation EGFRi [28]. This greater
selectivity has provided a therapeutic window that resulted in rapid
clinical success for osimertinib, with pooled analyses of the AURA ex-
tension and AURA2 clinical trials identifying a response rate (RR) of
66% and median PFS of 9.9 months in T790M-positive NSCLC patients
[29]. This data is comparable to the effect of first-generation EGFRi in
patients with classical EGFR mutations. The FDA granted accelerated
approval for osimertinib as a second-line treatment for EGFR T790M
mutant-positive patients following progression on erlotinib or gefitinib
in 2015 and regular approval for this indication in 2017 [30]. Inter-
estingly, recent clinical data from the FLAURA trial has also shown that
that osimertinib may be superior to first-generation EGFRi in the first-
line setting. Osimertinib provided superior median PFS of 17.2 months
compared to 8.5 months for gefitinib or erlotinib in treatment-naïve
NSCLC patients, resulting in FDA approval to treat patients with clas-
sical EGFR mutations with osimertinib as a first-line therapy in 2018
[31].
For further literature about EGFRi in NSCLC with classical EGFR
mutations, the reader is directed to several excellent reviews on the
subject [7,14,32,33]. The remainder of this review will discuss the
preclinical and clinical studies that have focused on NSCLC with rare
EGFR mutations.
3. Rare EGFR exon 18 mutations
3.1. E709X and exon 18 deletions
E709 is located in the N-lobe, on the N-terminal side of the β1
strand that immediately precedes the phosphate binding loop (Fig. 2).
Mutations at E709 are comprised of the deletion delE709-T710insD
(also referred to as exon 18 deletion) and substitutions of E709 for A, G,
K, or V, of which E709K is the most common [34,35]. Together, these
mutations are reported to account for ˜1.5% of rare EGFR mutations in
NSCLC, although the actual frequency of E709X and exon 18 deletions
may be underreported as they are not detectable by many common
commercially available diagnostic kits [35,36]. While delE709-
T710insD has been reported as a sole EGFR mutation, over 75% of
substitutions at E709 are reported as “complex mutations” with the
presence of additional EGFR mutations such as L858R, Ex19Del, or
G719X detected within the same tumour [35,37].
3.1.1. Preclinical data
To investigate E709X mutations, Kobayashi et al. expressed E709K
and delE709-T710insD in Ba/F3 and NIH-3T3 cells [34]. Ba/F3 cells
expressing E709X mutations were shown to grow in the absence of IL-3
while NIH-3T3 cells expressing the mutant constructs formed foci in a
focus formation assay, suggesting that these mutations are oncogenic
drivers. To examine the EGFRi sensitivity of these mutations, the au-
thors performed dose-response experiments on the Ba/F3 cells using 7
different EGFRi; first-generation inhibitors gefitinib and erlotinib,
second-generation inhibitors afatinib, dacomitinib and neratinib, and
third-generation inhibitors osimertinib and rociletinib. They found that
both E709K and delE709-T710insD were significantly less sensitive to
gefitinib, erlotinib, and osimertinib compared to Ba/F3 cells expressing
Ex19Del, with delE709-T710insD showing the greatest resistance to
these inhibitors. However, E709K and delE709-T710insD showed sen-
sitivity to the second-generation inhibitors afatinib and neratinib
comparable to that of Ex19Del. In parallel, western blot analysis of
HEK293 cells expressing E709K, delE709-T710insD, and Ex19Del re-
vealed that the tyrosine phosphorylation of EGFR was inhibited in each
cell line following treatment with afatinib or neratinib. In contrast, only
Ex19Del showed EGFR inhibition following treatment with the same
dose of gefitinib, erlotinib, or osimertinib, indicating that second-gen-
eration EGFRi have the greatest affinity for rare E709X and exon 18
deletion mutant EGFR compared to first- or third-generation inhibitors
3.1.2. Clinical data
The results of trials which have evaluated outcomes of NSCLC pa-
tients with rare EGFR mutations in exon 18 are summarised in Table 1.
As a result of the low incidence of E709X substitution and exon 18
deletion mutations, very little is known about the clinical response of
these mutations to EGFRi. Kobayashi et al. reported 53% RR across 15
patients with E709X complex mutations and 25% RR in 4 delE709_-
T710insD patients treated with first-generation EGFRi [8]. This data
supports the preclinical evidence that identified substitution mutations
at E709 as more sensitive to first-generation EGFRi overall compared to
exon 18 deletions [34]. A report assessing the use of afatinib identified
drug activity with time to treatment failure (TTF)> 12 months in 4
patients with E709X mutations [38], however all patients had complex
mutations with either additional L858R or G719X EGFR mutations.
Further clinical studies will be required to validate preclinical data that
second-generation EGFRi are more effective for E709X mutations,
which in turn may depend on uptake of diagnostic tests that can detect
these rare EGFR variants.
3.2. G719X
Among rare EGFR mutations in NSCLC, G719X substitutions (which
include G719S, G719A, G719C and G719D substitutions) are one of the
more commonly observed mutations second only to exon 20 insertions
and represent approximately 1.5–3% of all EGFR mutations in NSCLC
[8]. G719X mutations can occur as independent EGFRmutations or may
be present in combination with additional point mutations such as
S768I or L819Q as complex EGFR mutations [41].
3.2.1. Preclinical data
G719 is located in the phosphate binding “P-loop” within the N-lobe
(Fig. 3), which participates in the coordination of ATP by arching over
the triphosphate moiety. The P-loop also contributes to a set of
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hydrophobic interactions that hold the αC-helix in the inactive con-
formation. P723, which lies at the C-terminal end of the P-loop, packs
together with L747 and L862 to form a hydrophobic cluster sur-
rounding L858 [11]. In this conformation, a glycine at position 719 is
favoured. Substitution of glycine for serine at 719 reduces the flexibility
of the P-loop and weakens the hydrophobic interactions that hold the
αC-helix in the inactive conformation, leading to a 10-fold increase in
kinase activity compared to WT EGFR [11,12]. Shan et al. predict that
the structural changes induced by G719S mutation also increase pro-
pensity for dimerization and subsequent activation of EGFR in a similar
fashion to the L858R classical mutation. Substitution of G719 for A, C,
and D has also been reported in NSCLC [39]. Yun et al. suggest that
substitution for any non-glycine residue at position 719 would weaken
the hydrophobic interactions that hold the αC-helix in the inactive
conformation [11].
Kobayashi et al. showed that Ba/F3 cells expressing G719A mutations
were more sensitive to second-generation EGFRi than first-generation
EGFRi in vitro [34]. They found that G719A showed poor response to
gefitinib, erlotinib, and osimertinib when compared with cells expressing
Ex19Del. However, they showed that cells expressing G719A were sen-
sitive to the second-generation EGFRi afatinib and neratinib, with IC90 s
of 0.9 nM and 1.1 nM respectively. Western blot analysis showed that this
difference in sensitivity to EGFRi correlated to a decrease in EGFR
phosphorylation following drug treatment. When treated with up to 1 μM
of first-generation or third-generation EGFRi G719A cells retained EGFR
phosphorylation. However, when treated with just 10 nM of afatinib, the
G719A mutant cells almost entirely lost EGFR phosphorylation.
3.2.2. Clinical data
In one of the largest clinical studies focused on uncommon EGFR
mutations, Chiu et al. assessed the effectiveness of gefitinib and erlo-
tinib in 78 patients with single G719X mutations compared to common
Ex19Del and L858R mutations [39]. Although patients with single
G719X mutations were sensitive to EGFRi treatment (overall response
rate (ORR)=36.8%, disease control rate (DCR)= 72.4%, n=78),
they were markedly less sensitive when compared to L858R mutations
(ORR=67.5%, DCR=95.6%, n=256) or Ex19Del (ORR=65.3%,
DCR=94.5%, n=222). These findings were coupled with poorer
patient outcomes, with a median PFS of 6.3 months for G719X patients
compared to a median PFS of between 10–13 months for L858R and
Ex19Del patients. In line with preclinical studies, second-generation
EGFRi have been shown to be more effective than first-generation in-
hibitors in G719X patients [34]. In an early phase II clinical trial for
neratinib (NCT00266877), despite disappointing results for EGFR mu-
tant lung cancer overall, three out of four patients with the rare EGFR
mutation G719X showed a partial response to neratinib, whilst the
fourth exhibited stable disease for 40 weeks [21]. However, severe
dose-limiting toxicities for neratinib were observed during this trial
which halted further investigation of neratinib for EGFR-mutant NSCLC.
G719X mutations have also been shown to be responsive to the second-
generation EGFRi afatinib. A post-hoc analysis of data from 32 patients
pooled from LUX-Lung 2, LUX-Lung 3 and LUX-Lung 6 trials revealed
clinical activity of afatinib against rare EGFR mutant (G719X, S786I,
L861Q) lung cancers [9]. Across 8 patients harbouring single G719X
mutations and 6 with complex G719X mutations, afatinib treatment
resulted in 77.8% RR and 13.8 months PFS (Table 1), which in January
2018 led the FDA to broaden the indication for afatinib to include
NSCLC patients that harbour G719X mutations [10]. A recent phase II
trial has suggested that the third-generation inhibitor osimertinib may
also have clinical activity in this patient population, with 52.6% RR
reported in 19 patients harbouring G179X mutations [112]. However,
further trials will be required to determine whether osimertinib can
provide significant survival benefits compared to afatinib treatment.
4. Rare EGFR exon 19 mutations
4.1. Exon 19 insertion
Low prevalence exon 19 insertions have been reported that account
for approximately 2% of exon 19 aberrations and 1% of all EGFR mu-
tations in NSCLC [42]. Exon 19 insertions are characterised by 18 base
pair insertions that result in the addition of a 6 amino acid sequence
that, in the majority of cases, begins at codon 744 or 745 of the EGFR
gene. Although the exact amino acid sequence inserted is hetero-
geneous, the 4 amino acid sequence PVAI is shared and common to all
reported exon 19 insertions.
Table 1
Clinical outcomes of NSCLC patients with rare EGFR mutations in exon 18 after EGFRi treatment.





E709X Wu & Shih [35] DelE709-T710insD, n= 5 Gefitinib / Erlotinib 50.0% 72.2% 6.2 29.3
E709X complex mutations, n= 13
Kobayashi & Mitsudomi
[8]
DelE709_T710insD, n= 4 Gefitinib / Erlotinib 25.0% 50.0% NR NR
E709X complex mutations, n= 15 53.0% 86.7% NR NR
G719X Chiu et al. [39] G719X, n=78 Gefitinib / Erlotinib 36.8% 72.4% 6.3 NR
G719X+ L861Q, n= 9 88.9% 100.0% 11.9 NR
G719X+ S768I, n= 10 50.0% 100.0%
Kobayashi & Mitsudomi
[8]
G719X, n=148 Gefitinib / Erlotinib 65.5% 32.0% NR NR
G719X complex, n= 58 59.0% 89.7% NR NR
Kate et al. [108] G719X, n=5 Gefitinib / Erlotinib 50.0% NR 9.0 (NE) NR
Xu et al. [40] G719X, n=14 Gefitinib / Erlotinib /
Icotinib




Sequist et al. [21] G719X, n=4 Neratinib 75.0% 100.0% 12.1 NR
Yang et al. [9] G719X single, n= 8, + G719X complex,
n= 6
Afatinib 77.8% NR 13.8 (6.8 - NE) 26.9 (16.4 - NE)
Ahn et al. [112] G719X n= 19 Osimertinib 52.6% NR NR NR
Pooled Beau-Faller et al. [41] Total n=18: G719X, n=14, E709X,
n= 2,
Gefitinib / Erlotinib 7.0% 33.3% 3 (1 - NE) 22 (1 - 44)
rare exon 18 substitutions, n=2
Passaro et al. [113] Total n=42: G719X, n=35, E709X,
n= 3,
Gefitinib / Erlotinib /
Afatinib
31.0% 69.0% 8.3 (4.8 - 11.7) 17 (8.2 - 25.7)
not specified, n= 4
Legend: EGFRi, EGFR inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; DCR, disease control rate; SD, stable disease; PFS,
progression-free survival; CI, confidence interval; OS, overall survival; NR, not reported; NE, not estimable.
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4.1.1. Preclinical data
Despite nuanced differences in the exact sequence of exon 19 inser-
tions mutations, there are 2 conserved effects on the 3D structure; the
addition of the 6-residue sequence to the loop that connects the β3-strand
to the αC-helix (Fig. 3), and the alteration of E746 and L747, the last 2
residues of the β3-strand in WT EGFR. Insertion of the 6-residue sequence
is likely to be well tolerated as this loop is flexible in the structure of WT
EGFR. The shift in amino acids that alters the identity of the E746 residue
following insertion of a 6-residue sequence is also likely to have little
structural effect as it is exposed on the surface of the kinase. By contrast,
the L747 residue participates in a crucial hydrophobic core that stabilizes
the inactive form of the kinase domain. He et al. report 11 patients har-
bouring exon 19 insertions and in each patient a common effect of the
insertion is that the identity of the leucine residue at position 747 in WT
EGFR is changed to a proline residue at that position (L747P). L747P is
predicted to disfavour the formation of this hydrophobic core and thereby
lead to constitutive activation of EGFR; a mechanism analogous to that of
the L858R substitution, which lies immediately adjacent to L747 in the
hydrophobic core.
To assess the sensitivity of exon 19 insertions mutations to EGFRi,
He et al. expressed 2 different exon 19 insertions (I744_K745insKIPVAI
and K745_E746insTPVAIK) constructs in Ba/F3 cells [42]. Dose-re-
sponse experiments revealed that these exon 19 insertions showed a
similar sensitivity to gefitinib and afatinib compared to Ba/F3s ex-
pressing Ex19Del. Western blot analysis of NIH-3T3 cells expressing
exon 19 insertions revealed a loss of EGFR phosphorylation following
gefitinib or afatinib treatment comparable to that observed in Ex19Del
expressing cells. This data led the authors to conclude that exon 19
insertions mutations are EGFRi sensitive and recommends that NSCLC
patients harbouring these mutations should be treated with EGFRi.
4.1.2. Clinical data
Similar to E709 deletions and point mutations, exon 19 insertions
are not commonly screened as part of routine diagnosis and therefore
clinical data regarding EGFRi sensitivity is extremely limited. In a small
case report, He et al. reported that 3 out of 4 patients with metastatic
NSCLC harbouring exon 19 insertions showed a partial response to
EGFRi, providing evidence to suggest exon 19 insertions may confer
EGFRi sensitivity similar to classical EGFR mutations [42]. Several
other case studies have reported partial responses or stable disease for
small numbers of exon 19 insertion patients treated with first-genera-
tion EGFRi, however the durability of response has been extremely
variable, ranging from a relatively short PFS of 5.9 months to a much
longer 24 months [8,43–45] (Table 2). This preliminary data suggests
that exon 19 insertions could be considered EGFRi sensitive in the
clinical setting, however larger patient cohorts will be required to refine
which specific EGFRi provides effective and durable responses.
5. Rare EGFR exon 20 mutations
5.1. Exon 20 insertions
EGFR exon 20 insertion mutations encompass a heterogeneous
range of insertions of between 1–7 amino acids that occur towards the
C-terminal end of the αC-helix (Fig. 2 and 3) [46]. After classical mu-
tations, EGFR exon 20 insertions are the next most common EGFR
mutation in NSCLC, with frequencies reported at between 4–10% of all
observed EGFR mutations [46–48].
5.1.1. Preclinical data
Crystal structures of EGFR exon 20 insertion mutants have shown
that the insertion forms a wedge that “pushes” the αC-helix and pre-
vents its outward rotation into the inactive conformation, leading to
constitutive activation of the kinase domain [14,46]. Different EGFR
exon 20 insertion mutations display different sensitivity to EGFRi. Ya-
suda et al. found that A763_764insFQEA has a high affinity for first-
generation EGFRi gefitinib, whereas D770_N771insNPG did not. In vitro
kinetic studies revealed that D770_N771insNPG was able to activate
EGFR whilst retaining its ATP affinity, preventing competitive binding
of gefitinib [46]. Additionally, computational modelling has shown that
exon 20 insertions cause significant structural alterations in the P-loop
and αC-helix that result in a relatively small drug binding pocket that
sterically hinders first-generation EGFRi binding [49]. Conversely,
computational modelling of A763_764insFQEA suggests that insertions
that occur within the αC-helix, as opposed to within the loop following
the αC-helix, may have an activation mechanism more similar to that of
Ex19Del and L858R, and therefore would be predicted to be sensitive to
first-generation EGFRi [46].
A preclinical study utilized the Ba/F3 and NIH-3T3 model systems
to assess the sensitivity of 5 exon 20 insertion mutations to second-
generation EGFRi and noted that dacomitinib was particularly effective
for insertions that included a glycine residue at position 770 [50]. Dose-
response experiments showed that only cells expressing the D770de-
linsGY mutation were sensitive to a low enough in vitro dose of daco-
mitinib (17.5 nM) that would predict drug sensitivity in patients, based
on the plasma concentrations of dacomitinib achieved after a standard
dosing regimen of 45mg once per day in a phase II trial [51].
The preclinical evidence to support the use of third-generation
EGFRi for exon 20 insertions remains unclear. Third-generation EGFRi
osimertinib and rociletinib have shown poor responses in a study of two
lung cancer patient-derived xenograft models harbouring
P772_H773insDNP and H773_V774insNPH exon 20 insertion mutations
[52]. However, another study has shown significant anti-tumour ac-
tivity of osimertinib in xenograft models of the WT EGFR lung cancer
cell line H2073 cells engineered to express either D770_N771insSVD or
Table 2
Clinical outcomes of NSCLC patients with rare EGFR mutations in exon 19 after EGFRi treatment.





Ex 19 insertion Kobayashi & Mitsudomi [8] Exon 19 insertion, n= 10 Gefitinib / Erlotinib 40% 100% NR NR
He et al. [42] p.K745_E746insIPVAIK, n= 1 Afatinib PR 14 NR
p.K745_E746insTPVAIK, n=1 Erlotinib PR 19 NR
p.I744_K745insKIPVAI, n= 1 Erlotinib PR 50 NR
Unspecified exon 19 insertion, n= 1 XL674 NR 4 NR
Park et al. [114] p.I744_K745insKIPVAI, n= 1 Gefitinib PR 4.2 NR
p.I744_K745insKIPVAI, n= 1 SD 4.9 NR
p.I744_K745insKIPVAI, n= 1 PR 8.8 NR
Iyevleva et al. [115] p.I744_K745insKIPVAI, n= 1 Gefitinib PR 5 NR
p.I744_K745insKIPVAI, n= 1 SD 11+ NR
p.I744_K745insKIPVAI, n= 1 SD 9+ NR
Legend: EGFRi, EGFR inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; DCR, disease control rate; SD, stable disease; PFS,
progression-free survival; CI, confidence interval; OS, overall survival; NR, not reported; +, continued SD at date of last follow-up.
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V769_D770InsASV insertions using CRISPR [53]. While osimertinib
may not be effective for all EGFR exon 20 insertions, it is possible that
the sensitivity to third-generation EGFRi may be variable due to the
heterogeneity of the exact location and size of specific mutations.
Recently, EGFRi with the capacity to target exon 20 insertion mu-
tations have been evaluated, of which poziotinib is the most clinically
advanced. Poziotinib differs structurally from other EGFRi; it has a
flexible quinazoline core and small linking groups that, based on 3D
modelling, has been predicted to bind tightly to the restricted drug-
binding pocket of exon 20 insertion EGFR kinases [49]. Robichaux et al.
expressed 7 different EGFR exon 20 insertion mutations in Ba/F3 cells.
Dose-response experiments showed that cells expressing EGFR exon 20
insertion mutations were sensitive to low doses of poziotinib and con-
comitantly that mutant EGFR phosphorylation was potently reduced
following poziotinib treatment [49].
In addition to poziotinib, several other compounds that inhibit exon
20 insertion mutations are being investigated in preclinical studies.
TAK-788 is an irreversible inhibitor that selectively targets exon 20
insertion mutations. In preclinical studies utilizing the Ba/F3 model
system, Gonzalvez et al. showed TAK-788 to be effective against 14
different exon 20 insertion mutations [54]. The authors also showed
tumour regression in a patient-derived xenograft NSCLC model har-
bouring an exon 20 insertion mutation following treatment with TAK-
788. TAS6417 is a covalent inhibitor that binds irreversibly to C797 in
the ATP binding site of the exon 20 insertion mutant kinase [55]. Cell
free in vitro kinase assays showed that TAS6417 has selectivity for
D770_N771insNPG over WT EGFR. Western blot analysis found that
TAS6417 was able to inhibit EGFR phosphorylation in NIH-3T3 cell
lines expressing 6 different exon 20 insertion mutations. In the absence
of a cell line model harbouring an endogenous EGFR exon 20 insertion,
Hasako et al. employed transcription activator-like effector nuclease
(TALEN) mutagenesis to engineer a model based on the H1975 EGFR
mutant L858R/T790M cell line. In a two-step process, TALEN was first
used to introduce D770_N771insSVD into H1975 cells and subse-
quently, the endogenous L858R/T790M EGFR mutation was deleted.
TAS6417 was shown to inhibit cell growth of the H1975 EGFR
D770_N771insSVD mutant cell line in vitro and in vivo. Western blot
analysis of tissue collected from mice bearing H1975 EGFR
D770_N771insSVD tumours revealed that TAS6417 is able to inhibit
EGFR phosphorylation within the tumour, whilst having minimal effect
on WT EGFR phosphorylation within the skin tissue. Another study has
identified Compound 1A, a covalent inhibitor that also binds irrever-
sibly to C797 and may be effective against EGFR exon 20 insertions
[56]. The structure of compound 1A is based on the original pyrimidine
core of osimertinib, but unlike the third-generation EGFRi, this novel
drug possesses additional groups that form more extensive interactions
with a deep hydrophobic pocket of the EGFR kinase. Compound 1A has
been shown to potently inhibit phosphorylation of EGFR in Ba/F3 cells
expressing exon 20 insertion mutations and has shown anti-pro-
liferative effects against a patient-derived NSCLC cell line harbouring
an EGFR P772_H773insPNP mutation. Currently, the use of compound
1A in vivo is likely to be limited by poor oral bioavailability (11%) and
short half-life (0.5 h), however, further development may yield a
compound with improved pharmacokinetic properties that utilises this
mechanism to target EGFR exon 20 insertion kinases.
5.1.2. Clinical data
Clinical trials which have evaluated EGFRi in NSCLC patients with
rare EGFR mutations in exon 20 are summarised in Table 3. Clinical
studies have revealed notable differences in EGFRi sensitivity for dis-
tinct types of exon 20 insertions within this heterogeneous group of
mutations that supports preclinical observations. The majority of
NSCLC patients harbouring EGFR exon 20 insertions are resistant to
first- and second-generation EGFRi, with low response rates of between
0–27% reported [9,21,41,57]. However, as predicted by structural data
and kinetic analysis of drug binding in vitro, insertions that occur in the
portion of the EGFR gene which encodes the αC-helix, as opposed to
within the loop that immediately follows, are the exception to the rule
[46]. Multiple reports have demonstrated partial responses to erlotinib
for patients harbouring the A763_Y764insFQEA insertion, which dis-
plays similar sensitivity to first-generation EGFRi as classical EGFR
mutations [47,57,58]. Although currently licensed EGFRi have not
shown any significant benefit for patients with other EGFR exon 20
insertions, emerging EGFRi including poziotinib, TAK-788 and tarlox-
otinib are in clinical development with promising activity for this
subgroup of NSCLC patients. Further details of these drugs have been
recently reviewed in depth by our laboratory elsewhere [59].
5.2. S768I
In addition to exon 20 insertions, the point mutation S768I occurs in
the region that encodes the αC-helix in exon 20 of the EGFR gene
(Fig. 3) and has been reported at a frequency of between 0.6–1% of
EGFR mutations in NSCLC [8,60]
5.2.1. Preclinical data
Molecular dynamics simulations have shown that S768I stabilizes
an active αC-in conformation by improving the hydrophobic packing
between the αC helix and the adjacent β9 strand [12]. Banno et al.
found that Ba/F3 cells expressing EGFR S768I were less sensitive to
first-generation and third-generation EGFRi compared to the L858R
mutation [61]. Western blot analysis revealed that S768I expressing
Ba/F3s retained EGFR phosphorylation following treatment with 100
nM of erlotinib or osimertinib, whereas L858R expressing cells had
reduced EGFR phosphorylation under the same conditions. However,
S768I expressing cells did possess sensitivity to afatinib that was com-
parable with L858R, and treatment with 10 nM afatinib was sufficient
to reduce S768I EGFR phosphorylation. Although no NSCLC lines har-
bouring endogenous S768I are commercially available, Bann et al.
studied the oesophageal cancer cell line KYSE540 that expresses har-
bour endogenous S768I [61]. Dose-response experiments and western
blot analysis of this cell line showed comparable results to the Ba/F3
model system, providing further evidence that S768I is resistant to first-
generation and third-generation EGFRi compared to L858R, but sensi-
tive to the second-generation EGFRi afatinib.
5.2.2. Clinical data
Whilst the S768I mutation can occur in isolation, it is more common
that S768I co-occurs with additional point mutations in EGFR to form
complex mutations, which can confound interpretation of the clinical
data. For example, large variation in responses to first-generation
EGFRi have been reported across multiple case studies of S768I mutant
patients, ranging from no response and progressive disease [62,63], to
good partial responses and intermediate sensitivity [60,64–66]. High-
lighting the heterogeneity of durability of response, Leventakos et al.
reported a wide range of 3–30 months PFS across 9 patients with either
isolated S768I mutation or S768I/G719X or S768I/L858R complex
mutations [60]. The low frequency of these mutations and the varia-
tions in co-occurring EGFR point mutations present a significant chal-
lenge in dissecting the reasons behind these inconsistencies in the
clinical data. Interestingly, Chiu et al. observed that the complex mu-
tation S768I/G719X may be more sensitive to first-generation EGFRi
treatment compared to the single S768I point mutation alone, with 50%
RR (n=10) for complex S768I mutations vs. 33% RR (n= 7) for single
S768I mutation [39]. Preclinical data suggested the second-generation
inhibitor afatinib may be more effective than first-generation inhibitors
for S768I mutant EGFR [61]. In the post-hoc analysis of the LUX-Lung
2, LUX-Lung 3 and LUX-Lung 6 trials, the second-generation EGFRi
afatinib achieved 100% ORR and 14.7 months median PFS for 8 pa-
tients with S768I mutant NSCLC leading to FDA approval of this drug
for NSCLC patients with EGFR S768I mutations [9]. Notably however,
within this analysis, 7 out of 8 of the S768I mutant patients harboured

















































































































































































































































































































































































































































































































































































































































































































































































































































































P.T. Harrison, et al. Seminars in Cancer Biology 61 (2020) 167–179
173
complex mutations with either G719X or L858R mutations and there-
fore it remains unclear whether afatinib will demonstrate consistent
responses for patients with single S768I point mutations without studies
in larger cohorts.
6. Rare EGFR exon 21 mutations
6.1. L861Q
L861Q is located within the activation loop of EGFR (Fig. 3) and
accounts for around 3% of EGFR mutations in NSCLC [61,67].
6.1.1. Preclinical data
Molecular dynamics simulations have shown that L861Q stabilizes
an active αC-in conformation through the formation of new H-bonds
near the C-terminal of the αC-helix [12]. Studies of L861Q in the Ba/F3
model system demonstrated that similar to S768I mutations, L861Q is
resistant to first-generation EGFRi compared to L858R, but unlike
S768I, L861Q was sensitive to both afatinib and osimertinib treatment
[61]. This correlates with western blot analysis showing that EGFR
phosphorylation was retained in cells expressing L861Q following
treatment with erlotinib, but was lost following treatment with 10 nM
afatinib or 100 nM osimertinib. The oesophageal cancer cell line
KYSE270 that harbours an endogenous EGFR L861Q mutation also
showed comparable results to the Ba/F3 model system. These data
suggest that both second- and third-generation inhibitors may be ef-
fective to target L861Q mutations.
6.1.2. Clinical data
The results of clinical trials which have evaluated EGFRi in L861Q
mutant NSCLC are summarised in Table 4. In the largest cohort re-
ported of 57 patients with L861Q mutations, Chiu et al. observed a 40%
RR to first-generation EGFRi, suggesting an intermediate sensitivity
comparable to S768I and G719X point mutations [39]. This finding
supports preclinical observations that L861Q mutations have a reduced
sensitivity to first-generation EGFRi compared to L858R, that is similar
to the S768I and G719X mutations [8,61]. Post-hoc analysis of the LUX-
lung trials revealed afatinib treatment resulted in a 56% RR and 8.2
months median PFS across 12 patients with single L861Q point muta-
tions, 3 patients with L861Q/G719X, and 1 patient with L861Q/
Ex19Del complex mutations [9]. These data support preclinical evi-
dence that L861Q mutations are sensitive to afatinib, and led to FDA
approval for afatinib for L861Q mutant positive NSCLC [10]. A phase II
trial for osimertinib reported partial response in 77.8% of patients with
L861Q mutations (n = 9) [112]. These data support the preclinical
observation that L861Q mutations are sensitive to third-generation
EGFRi [61] and suggests that osimertinib may be an effective treatment
option for patients harbouring L861Q mutations.
7. Other rare EGFR mutations
7.1. EGFR kinase domain duplication (EGFR-KDD)
EGFR-KDD is most commonly a duplication of exons 18–25 or exons
18–26, which encodes the tyrosine kinase domain, although cases of
duplication of exons 14–26 and 17–25 have been reported [68]. EGFR-
KDD was first described in NSCLC in 2015 following next generation
sequencing of a tumour specimen derived from a patient that displayed
durable response to erlotinib despite no detectable common EGFR
mutations by a polymerase chain reaction-based assay [69]. Although
the exact frequency of EGFR-KDDs is uncertain in the absence of routine
diagnostic NGS, multicentre studies have reported EGFR-KDDs at 0.2%
(n= 1510) [70] and 0.24% (n= 5394) [68] of EGFR-mutant NSCLC
patients, indicating that duplications may be one of the rarest types of
EGFR mutation in lung cancer.
7.1.1. Preclinical data
When expressed in NR6, a mouse fibroblast cell line, and Ba/F3 cells
EGFR-KDD displayed high levels of constitutive receptor phosphoryla-
tion compared to WT EGFR [71]. Gallant et al. also found that A1235
cells, a human glioblastoma cell line which harbours endogenous EGFR-
KDD, showed high levels of constitutive EGFR phosphorylation in the
presence and absence of serum. Computational modelling revealed that
EGFR-KDD are capable of forming intramolecular N-lobe to C-lobe
asymmetric dimers, which result in constitutive activation of the re-
ceptor [71]. To assess the sensitivity of EGFR-KDD to currently avail-
able EGFRi, Gallant et al. treated Ba/F3 cells expressing EGFR-KDD
with erlotinib, afatinib, and osimertinib. They found that EGFR-KDD
was most sensitive to afatinib. They also showed that phosphorylation
of the downstream signalling node ERK decreased following EGFRi
treatment, observing similar results in NR6-EGFR-KDD and A1235 cells,
indicating that ERK signalling is important for EGFR-KDD-dependent
cell survival.
7.1.2. Clinical data
EGFR-KDD has been reported in patients without any additional
EGFR mutations, supporting the preclinical evidence that duplication of
the kinase domain alone can function as an oncogenic driver in NSCLC
(Table 5). Although clinical data is limited for this rare mutational
event, evidence reported thus far suggests that EGFR-KDD confers
sensitivity to targeted EGFRi. In a case report presented by Baik et al., a
lung cancer patient harbouring EGFR-KDD demonstrated a durable
partial response to second-line treatment with gefitinib for 6 years until
disease progression [69]. Following a short regimen of chemotherapy
and pemetrexed, which was discontinued due to disease progression,
rechallenge with erlotinib in this patient as a fourth-line therapy led to
tumour response for a further 3 years. In another case report, Gallant
Table 4
Clinical outcomes of NSCLC patients with rare EGFR mutations in exon 21 after EGFRi treatment.





L861Q Chiu et al. [39] L861Q, n=57 Gefitinib / Erlotinib 39.6% 75.5% 8.1 NR
L861Q+G719X, n= 9 88.9% 100.0% NR NR
Xu et al. [40] L861Q, n=15 Gefitinib / Erlotinib /
Icotinib




Kate et al. [108] L861Q, n=2 Erlotinib 0.0% 0.0% 1.8 (NE) NR
Kobayashi & Mitsudomi
[8]
L861Q, n=64 Gefitinib / Erlotinib 39.0% 77.0% NR NR
L861Q complex, n= 12 92.0% 100.0% NR NR
Yang et al. [9] L861Q single, n= 12, + L861Q
complex, n=4
Afatinib 56.3% NR 8.2 (4.5 - 16.6) 17.1 (15.3 -21.6)
Ahn et al. [112] L861Q n= 9 Osimertinib 77.8% NR NR NR
Legend: EGFRi, EGFR inhibitor; ORR, objective response rate; CR, complete response; PR, partial response; DCR, disease control rate; SD, stable disease; PFS,
progression-free survival; CI, confidence interval; OS, overall survival; NR, not reported; NE, not estimable.
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and colleagues identified a NSCLC patient with EGFR-KDD who showed
a partial response following 2 cycles of afatinib treatment [71]. Ac-
quired resistance developed after 7 cycles of afatinib, with amplifica-
tion of EGFR-KDD detected – implicating increase in oncogene dosage
by amplification of EGFR-KDD as a mechanism of resistance to afatinib
therapy.
In the largest multicentre study focused on clinical outcomes of
EGFR-KDD to targeted therapy, Wang et al. reviewed 10,759 East Asian
NSCLC patients who underwent NGS and identified 13 EGFR-KDD po-
sitive patients in total, of which 5 patients were treated with targeted
therapy [68]. Two out of 5 patients did not respond to treatment with
EGFRi including gefitinib, erlotinib and osimertinib and experienced
disease progression with a short PFS of less than 3 months. The re-
maining 3 patients demonstrated either partial response to EGFRi for a
minimum of 4 months with disease progression not yet reached at the
time of publication, or stable disease for 11 months (summarised in
Table 5). Collectively, these studies suggest that despite some hetero-
geneity in patient response, EGFR-KDD mutations are targetable by
EGFRi. Additionally, both T790M mutation [68,69] and EGFR-KDD
amplification [68,71] were reported in biopsies of EGFR-KDD tumour
specimens post EGFRi treatment, suggesting shared resistance me-
chanisms with classical EGFR mutations to targeted therapy [72,73].
7.2. Complex mutations
In the context of EGFR mutations in NSCLC, the term “complex” or
“compound” can refer to 3 possible scenarios: 1) classical L858R or
Ex19Del EGFR mutations that also harbour additional EGFR mutations
(classical+ rare), 2) a combination of multiple, distinct, rare EGFR
mutations that co-occur on the same allele (rare+ rare), or 3) a com-
bination of both L858R and Ex19Del EGFR mutations (clas-
sical+ classical). Complex mutations have been reported account for ˜5
– 15% of EGFR mutations in NSCLC [65,74–76].
7.2.1. Preclinical data
Performing EGFR exon sequencing on a cohort of NSCLC specimens,
Kohsaka et al. report that over 90% of G719X mutations examined
(n=15) exist as complex mutations. Additionally, they report that over
75% of E709X mutations in the COSMIC database (n = 102) also exist
as complex mutations [37]. Droplet Digital PCR (ddPCR) revealed that
all compound mutations were present in cis alleles. Kohsaka et al. ex-
pressed a panel of rare mutations either alone or in combination in trans
or in cis with L858R, G719A, G719C, or Ex19Del in NIH-3T3 and Ba/F3
cell line models. They found that NIH-3T3 cells expressing the complex
mutations in cis formed more foci than either the single mutation or the
complex mutations in trans. Taken together with the ddPCR data, this
finding suggests that the transformation potential of complex mutations
is higher than that of a rare EGFR mutation alone. The response of in-
dividual and complex EGFR mutations to gefitinib, erlotinib, afatinib
and osimertinib were assessed using a high-throughput screen in which
Ba/F3 cells expressing different mutations were uniquely barcoded and
pooled together, with detection of barcodes by deep sequencing used to
estimate relative cell numbers. For gefitinib, erlotinib and osimertinib
treatment, the IC50 value for each complex EGFR mutation was inter-
mediate between each corresponding single EGFR mutation. For ex-
ample, the IC50 value for gefitinib treatment of L858R alone (4.4 nM)
was lower than L858R+E709A (259 nM), but the complex mutation
was more sensitive to drug treatment versus the single E709A rare
mutation (785.8 nM). Interestingly, these differences were not observed
for the irreversible second-generation EGFRi afatinib, which potently
inhibited cell viability at similar levels across all single and complex
EGFR mutations tested.
7.2.2. Clinical data
EGFR complex mutations encompass a broad spectrum of different
mutation combinations and as such a wide range of patient responses to
EGFRi is expected. Nevertheless, with the exception of known re-
sistance mutations such as T790M, complex EGFRmutations give rise to
more favourable patient outcomes in response to EGFRi compared to
single rare mutations alone [35,39,41,77]. In particular, the co-occur-
rence of a rare EGFR mutation with a classical L858R or Ex19Del mu-
tation may be a strong indicator of sensitivity to EGFRi [40,78]. Baek
et al. reported median PFS of 7.4 months for complex classical and rare
mutation combinations following EGFRi treatment and 5.1 months for
complex rare and rare mutation combinations. In both cases median
PFS was significantly longer compared to patient groups of single rare
exon 18 point mutations or exon 20 insertions (1.3 months and 2.6
months median PFS respectively) [78]. This supports preclinical data
that demonstrate that complex mutations are more sensitive to EGFRi
than single rare mutations [37]. Within rare and rare complex EGFR
mutation combinations, it is likely that the sensitivity to EGFRi is in-
fluenced by the specific co-occurring partner mutation. For example,
Chiu et al. observed differences in RR between G719X+ L861Q
(88.9%) versus G719X+S768I (50%) [39]. L858R+Ex19Del complex
mutations achieved median 9.5 months PFS following EGFRi therapy
[40], which is similar to the median PFS reported in patients with single
L858R or Ex19Del mutations, indicating equivalent sensitivity of this
class of complex mutations to the corresponding single mutation. Larger
clinical studies informed by in vitro preclinical data will need to be
conducted in order to predict the mutation combinations with the
greatest sensitivity to EGFRi. Although patients with single classical
EGFR mutations achieve the best clinical responses to EGFRi, these
studies suggest that in most cases, patients with complex mutations
show better clinical responses to EGFRi compared to patients with
single rare EGFR mutations. In contrast, clinical responses are not as
good for complex mutations that include a primary mutation that has
been linked to resistance to first- or second-generation EGFRi, such as
T790M. A poor RR of 8.3% and median PFS of 1.4 months was reported
for patients that harboured complex EGFR mutations that contained
either exon 20 insertions or T790M mutations [79].
Table 5
Clinical outcomes of NSCLC patients with EGFR kinase domain duplications after EGFRi treatment.
Mutation Study (Reference) EGFR mutation(s), n treated with
EGFRi
EGFRi used Response to EGFRi (PFS)
EGFR-KDD Baik et al. [69] EGFR-KDD exons 18-25, n= 1 Gefitinib > Erlotinib Gefitinib PR (6 years), erlotinib PR (5 years)
Gallant et al. [71] EGFR-KDD exons 18-25, n= 1 Afatinib PR (PFS NR)
Wang et al. [68] EGFR-KDD exons 18-25, n= 1 Erlotinib > Osimertinib Erlotinib PD (2 mo), osimertinib PD (2 mo)
EGFR-KDD exons 18-25, n= 1 Gefitinib > Afatinib > Osimertinib Gefitinib PR (5 mo), afatinib PD (2 mo), osimertinib PR (4 mo)
EGFR-KDD exons 18-25, n= 1 Gefitinib SD (11 mo)
EGFR-KDD exons 18-25, n= 1 Icotinib+Apatinib PR (4+ mo - PFS not reached)
EGFR-KDD exons 18-25, n= 1 Gefitinib > Erlotinib Gefitinib PD (3 mo), erlotinib PD (5 mo)
Legend: EGFRi, EGFR inhibitor; EGFR-KDD, EGFR kinase domain duplication; PR, partial response; SD, stable disease; PD, progressive disease; PFS, progression-free
survival; NR, not reported;
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8. Future perspectives
Structural data and preclinical models can shed light on the acti-
vation mechanisms of rare EGFR mutations and have been used to
predict the sensitivity of different mutations to EGFRi. This information
can translate into the identification of therapies that confer significant
survival benefit over conventional chemotherapy when a sufficient
patient population can be recruited and assessed in clinical trials, such
as the successful approval of afatinib to treat patients harbouring rare
G719X, S768I, or L861Q EGFR mutations [9]. The therapeutic land-
scape for classical EGFR-mutant NSCLC is rapidly evolving in response
to the development of novel EGFRi, immunotherapy and rational drug
combinations in order to determine the most effective and durable
treatment strategy. However, there remain several outstanding issues
that need to be addressed in order to ensure that research in rare EGFR
mutations keeps apace with this fast-moving field.
8.1. Outstanding issues for rare EGFR mutations in NSCLC
Despite significant progress in our understanding of the mechanisms
of receptor activation by rare EGFR mutations and the sensitivity of
different mutations to EGFRi, little is known about the effect that dif-
ferent EGFRmutations have on the interactome and signalling networks
downstream of EGFR. Neomorphic mutations within the same gene that
display distinct signalling pathway dependencies have been observed
elsewhere in cancer biology. For example, Cheung et al. noted muta-
tion-specific drug sensitivities when studying different mutations in the
PI3KR1 gene, encoding the PI3K subunit p85α, which frequently occur
across multiple cancer types [80]. Cheung et al. found that two muta-
tions that occur in a similar region of the PI3KR1 gene, the R348*
truncation and L370fs frameshift mutations, resulted in an increased
sensitivity to MEK and JNK inhibitors compared to WT and mutations
located elsewhere in the gene [80]. The authors show that R348* and
L370fs variants localize to the nucleus and provide a scaffold for com-
ponents of the nuclear JNK pathway, conferring a unique vulnerability
to disruption of MEK/JNK signalling pathways. These findings highlight
the need to tailor targeted therapies not just to the gene which is mu-
tated, but also toward the specific mutation within the gene. In the
context of rare EGFRmutations in lung cancer, little is known about the
differences in downstream signalling between distinct mutations. Mu-
tation-specific patterns of downstream signalling activation have been
observed when comparing EGFR WT with EGFR L858R and the
EGFRvIII and EGFRvIV found in glioblastoma [81–83]. Future work
will need to examine the interactome of different mutant receptors and
profile the downstream signalling networks activated by different rare
EGFR mutations. A deeper understanding of the biology of different
EGFR mutations may reveal mutation-specific dependencies that could
be exploited therapeutically through the use of combination strategies,
polytherapies, or synthetic lethal approaches [84,85].
The rarity of the mutations described here has led to the field being
frequently reliant on genetically engineered model systems. The use of
model systems such as Ba/F3 cells means that any cancer cell-type
specific effects are likely to be missed. To generate models which more
closely match the original cancer context, techniques including TALEN
or CRISPR have been recently used to genetically engineer lung cancer
cell lines to replace EGFR WT or classical EGFR mutations with the
desired rare EGFR mutations [53,55]. Such approaches allow the study
of rare mutations in a cellular context that is more relevant to the
clinical setting. Recently, a number of patient-derived cell lines and
xenografts harbouring endogenous exon 20 insertion mutations have
been generated [49,56,86]. These models have facilitated studies that
have advanced our biological understanding of exon 20 insertion mu-
tations, leading to the development of several compounds that target
this class of mutations. Future work focusing on the development of cell
lines harbouring other rare EGFR mutations from patients could lead to
similar advancements in our understanding of rare EGFR mutations and
how to treat them. Recent advances in generating patient-derived or-
ganoid models from NSCLC tumours can also be applied in this setting
to evaluate targeted drugs and guide treatment decisions for rare EGFR
mutations [87,88].
A major barrier to progress in the treatment of rare EGFR mutations
is the lack of clinical trials that focus specifically on rare mutations. The
clinical trials described in this review focus mainly on classical EGFR
mutations, with the majority of clinical findings that specifically pertain
to rare mutations coming from retrospective, multicentre analyses or
post-hoc analyses of pooled clinical trials [9]. Moving forwards, it is
important that patients with rare EGFR mutations are not excluded
from larger trials to enable these types of post-hoc analyses that can
determine the efficacy of EGFRi in the clinical setting. Increased uptake
of NGS in routine diagnostics will help to identify additional patients
with rare EGFR mutations that would be candidates for clinical trials. In
particular, E709X mutations, EGFR-KDD and certain exon 20 insertions
are not detected by commercially available PCR-based tests such as the
current commercially available cobas® EGFR Mutation Test v2 platform
(Roche). Given the heterogeneity of EGFRi response observed between
different mutations and the influence of complex mutations on EGFRi
sensitivity, caution must be taken to dissect the data to isolate muta-
tion-specific effects. For example, although 100% RR was observed for
afatinib in patients harbouring S768I mutations across LUX-Lung 2,
LUX-Lung 3 and LUX-Lung 6 trials, 7 out of the 8 patients assessed
harboured complex EGFR mutations [9,21,41,57]. Larger data sets are
required to determine if afatinib remains effective in patients with
S768I EGFR mutations alone. In an ideal setting, focused clinical trials
that aim to recruit patients with rare EGFR mutations should be con-
ducted to minimise patient heterogeneity. Several trials are already
ongoing for patients with EGFR exon 20 insertions to assess EGFRi in-
cluding osimertinib (NCT03414814), poziotinib (NCT03066206) [49],
TAK-788 (NCT02716116) and tarloxotinib (NCT03805841). Similar
trials for other rare EGFR mutations will help to refine therapeutic
decisions based on mutation type.
8.2. Emerging treatment strategies for mutant EGFR NSCLC
There is growing evidence to support the use immunotherapies in
the treatment of NSCLC, and several antibodies that target the PD1/PD-
L1 immune checkpoint have shown significant PFS and OS benefits
compared to chemotherapy in ˜20% of advanced NSCLC patients in-
cluding pembrolizumab, nivolumab, durvalumab and atezolizumab
[89–93]. However, a recent meta-analysis has highlighted that the same
survival benefits with immunotherapies are not present in NSCLC pa-
tients with classical EGFR mutations [94]. Nevertheless, rare EGFR
mutations have been associated with longer median PFS when treated
with immune checkpoint inhibitors [95]. Retrospective analysis of
EGFR mutant NSCLC patients treated with pembrolizumab or nivo-
lumab revealed that patients harbouring G719X and exon 20 insertion
mutations have longer median PFS compared to patients harbouring
classical mutations (8.4 months vs 1.6 months; Yamada et al., 2019).
Although encouraging, this study was conducted retrospectively using a
small sample size (n=27). Future clinical studies with larger sample
sizes are required to validate the efficacy of immunotherapies for other
rare EGFR mutations. Furthermore, it is necessary to establish whether
immunotherapies are superior to available EGFRi such as afatinib. Ya-
mada et al. report 8.4 months median PFS for patients harbouring ei-
ther G719X or exon 20 insertion mutations treated with pembrolizumab
or nivolumab compared to 13.8 months or 2.7 months median PFS for
G719X or exon 20 insertions respectively when treated with afatinib
[9,96,97]. These data suggest that immunotherapy may be a preferable
therapeutic option for exon 20 insertion mutations, but not for G719X.
Nonetheless, head-to-head trials comparing immunotherapies with
EGFRi will be necessary to establish the usefulness of immunotherapies
in the treatment of NSCLC with rare EGFR mutations.
A further obstacle to effective use of immunotherapies is the current
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lack of a predictive biomarker. Although PD-L1 expression has been
identified as predictive of response in clinical trials in NSCLC, median
OS following treatment with immunotherapy does not differ sig-
nificantly with PD-L1 expression within the EGFR mutant group
[89,90]. Similar findings have been reported in studies focusing spe-
cifically on rare EGFR mutations. A case report described 4 NSCLC
patients with uncommon EGFR mutations and high PD-L1 expression
(> 50%) [98]. Three of the 4 patients described harboured G719X
mutations, and were effectively treated with pembrolizumab. The re-
maining patient had a E746_T751delinsA+T790M compound muta-
tion and despite having 60% PD-L1 expression did not respond to
pembrolizumab treatment. Conversely, Gettinger et al. reported 2 out of
13 patients with EGFR mutations were alive at 5-year follow up of a
phase I study of nivolumab in NSCLC, both of whom harboured rare
mutations (G719A and exon 20 insertion mutation respectively) with
low PD-L1 expression (< 1%) [99]. The patient harbouring G719A
showed a partial response with progressive disease 16 months after
completion of the treatment protocol. Subsequent rechallenge with
nivolumab resulted in a second partial response and 8 months PFS. The
patient harbouring an exon 20 insertion mutation experienced 9
months PFS with nivolumab treatment. Overall these studies suggest
that immunotherapies may be effective for certain rare EGFR muta-
tions. However, they also demonstrate that the predictive value of PD-
L1 overexpression as a biomarker for response to checkpoint inhibition
in NSCLC with rare EGFR mutations remains unclear. To advance the
use of immunotherapies in rare EGFR mutations, future work will need
to focus on identifying a reliable predictive biomarker for response and
establishing whether immunotherapies confer superior survival benefits
compared to available EGFRi.
Another potential strategy is to combine EGFRi and immunotherapy
to achieve a more durable response. A combination of EGFRi and im-
munotherapy in vitro has suggested that short-term erlotinib treatment
is sufficient to enhance the susceptibility of NSCLC cell lines harbouring
classical EGFR mutations to cell killing by cytotoxic natural killer cells
and T cells, via an upregulation of caspase-mediated apoptosis [100].
This raises the exciting possibility that sequential or combinatorial
EGFRi and immunotherapy could delay the onset of resistance to tar-
geted therapies alone and enhance patient responses in the clinic.
Several clinical trials are ongoing to assess the combination of EGFRi
and immunotherapy either in the context of treatment-naïve or EGFRi-
resistant NSCLC [101]. Although the data from these trials are not
mature, minimal improvements have been observed for im-
munotherapy and EGFRi combination therapy versus EGFRi alone
[102]. However, the combination treatment has thus far only been
assessed in the classical EGFR mutation setting and is associated with a
high degree of grade 3 and 4 toxicities. Thus, further investigational
work is needed to clarify whether there is synergy between EGFRi and
immunotherapy in patients, which patients are most likely to benefit,
and what the optimal drug scheduling strategy will be.
Combination strategies involving conventional chemotherapy to-
gether with either EGFRi or immunotherapy are also being assessed in
EGFR mutant NSCLC. A recent phase III trial found that addition of pe-
metrexed-carboplatin to gefitinib significantly prolonged median PFS in
patients harbouring sensitizing mutations in exon 19, 21, or 18 compared
to gefitinib alone (16 months vs 8 months; [103]). These exciting results
raise the question of whether similar PFS benefits could be achieved in
patients harbouring rare EGFRmutations that are sensitive to other EGFRi
such as afatinib. Future clinical studies should assess the efficacy of pe-
metrexed-carboplatin in combination with afatinib for the treatment of
patients harbouring G719X, S768I, or L861Q mutations.
Although combination strategies of immunotherapy and che-
motherapy have shown efficacy for NSCLC patients without sensitizing
EGFRmutations [104], the usefulness of these therapies in patients with
EGFR mutant disease is unclear. While the IMpower150 trial found that
combination of atezolizumab with carboplatin+ paclitaxel+ bev-
acizumab provided a significant median PFS benefit compared to the
same treatment without atezolizumab in a patient group harbouring
either EGFR or ALK mutations (9.7 months vs 6.1 months; [105]), the
IMpower130 trial reported no benefit to patients harbouring EGFR
mutations when treated with atezolizumab+ chemotherapy [106]. It
should be noted that the IMpower130 trial did not include bev-
acizumab, an anti-VEGF-A humanised monoclonal antibody, in the
combination strategy, suggesting that bevacizumab may be important
for activity in EGFR mutant patients. The median PFS benefit reported
in the IMpower150 trial could be promising for the treatment of pa-
tients with rare EGFRmutations that do not respond to available EGFRi.
However, both the IMpower150 trial and the IMpower130 trial ex-
cluded patients with EGFR mutations from their primary end-points.
They also do not report the specific mutation in patients with EGFR
mutations, meaning that no conclusions can be reached regarding the
efficacy of immunotherapy – chemotherapy combinations in patients
harbouring rare EGFR mutations. Future work focused on patients
harbouring rare EGFR mutations will be required to assess the efficacy
of immunotherapy – chemotherapy combinations in this setting. An-
other important caveat to the usefulness of immunotherapy – che-
motherapy combinations is the increased toxicities associated with the
combination strategy. The KEYNOTE-189 trial that assessed pem-
brolizumab in combination with chemotherapy reported discontinua-
tion of treatment due to therapy related adverse events in 13.8% of
patients receiving pembrolizumab - chemotherapy compared to 7.9%
receiving placebo - chemotherapy [104]. Similarly, the KEYNOTE-407
trial reports discontinuation of treatment due to therapy related adverse
events in 13.3% of patients receiving pembrolizumab - chemotherapy
compared to 6.4% receiving placebo [107]. Establishing the safest ap-
proach to administering immunotherapy – chemotherapy combinations
will be essential in advancing the use of these strategies in patients
harbouring rare EGFR mutations.
9. Conclusion
Rare mutations in EGFR account for ˜15% of EGFR mutations in
NSCLC, amounting to around 30,000 diagnoses per year owing to the
high prevalence of lung cancer. Although many rare EGFR mutations
are associated with poorer responses to first-generation EGFRi com-
pared to classical EGFR mutations, more effective alternative EGFRi
have been identified for several rare EGFR mutations such as exon 20
insertions. It is therefore essential that there is an increased uptake of
improved detection methods such as NGS in clinical practice moving
forward in order to identify rare EGFR mutations and assign the most
effective EGFRi on a mutation-specific basis. The question of whether
different rare EGFR mutations harbour differences in their interactomes
or downstream signalling networks remains unanswered. In order to
fully address this biological question it will be necessary to develop
novel preclinical models of rare EGFR mutations. An improved under-
standing of the fundamental biology of different rare EGFR mutations
may identify mutation-specific dependencies that could be exploited
therapeutically. To address the paucity of clinical data pertaining to
rare EGFR mutations, future studies must not exclude patients with rare
EGFR mutations and should report PFS and OS data for each rare mu-
tation separately to facilitate pooled post-hoc analyses. Clinical trials
focusing specifically on rare EGFR mutations could significantly im-
prove the treatment options for patients harbouring rare EGFR muta-
tions.
Alternative strategies to EGFRi are also being assessed in EGFR
mutant NSCLC. Immunotherapies have shown efficacy in patients har-
bouring rare EGFR mutations, potentially opening new treatment stra-
tegies for patients whose mutations do not respond well to available
EGFRi. However, this exciting prospect is hampered by the small
sample sizes in current studies and the lack of predictive biomarkers.
Clinical trials with larger cohorts that focus on rare EGFRmutations and
the identification of robust predictive biomarkers are essential for the
advancement of these therapies in the clinic. Finally, combination of
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chemotherapy with gefitinib has led to longer median PFS in patients
harbouring classical EGFR mutations. Future clinical trials assessing
whether similar benefits can be achieved in patients with rare EGFR
mutations that are sensitive to afatinib could significantly improve the
treatment of patients with these mutations.
Acknowledgements
Our laboratory is supported by grants from the Institute of Cancer
Research and Cancer Research UK (C36478/A19281).
References
[1] R. Rosell, et al., Screening for epidermal growth factor receptor mutations in lung
cancer, N. Engl. J. Med. 361 (10) (2009) 958–967.
[2] S.P. D’Angelo, et al., Incidence of EGFR exon 19 deletions and L858R in tumor
specimens from men and cigarette smokers with lung adenocarcinomas, J. Clin.
Oncol. 29 (15) (2011) 2066–2070.
[3] E.A. Collisson, et al., Comprehensive molecular profiling of lung adenocarcinoma,
Nature 511 (7511) (2014) 543–550.
[4] Y. Shi, et al., A prospective, molecular epidemiology study of EGFR mutations in
asian patients with advanced non–small-cell lung cancer of adenocarcinoma his-
tology (PIONEER), J. Thorac. Oncol. 9 (2) (2014) 154–162.
[5] T.J. Lynch, et al., Activating mutations in the epidermal growth factor receptor
underlying responsiveness of non–small-cell lung cancer to gefitinib, N. Engl. J.
Med. 350 (21) (2004) 2129–2139.
[6] J.G. Paez, et al., EGFR mutations in lung Cancer: correlation with clinical response
to gefitinib therapy, Science 304 (5621) (2004) 1497–1500.
[7] A.F. Gazdar, Activating and resistance mutations of EGFR in non-small-cell lung
cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene 28
(Suppl 1) (2009) S24–31.
[8] Y. Kobayashi, T. Mitsudomi, Not all epidermal growth factor receptor mutations in
lung cancer are created equal: perspectives for individualized treatment strategy,
Cancer Sci. 107 (2016) 1179–1186.
[9] J.C.H. Yang, et al., Clinical activity of afatinib in patients with advanced non-
small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-
hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6, Lancet Oncol. 16 (7)
(2015) 830–838.
[10] FDA, FDA Broadens Afatinib Indication to Previously Untreated, Metastatic NSCLC
With Other Non-Resistant EGFR Mutations, FDA, 2018.
[11] C.-H. Yun, et al., Structures of lung cancer-derived EGFR mutants and inhibitor
complexes: mechanism of activation and insights into differential inhibitor sen-
sitivity, Cancer Cell 11 (3) (2007) 217–227.
[12] Y. Shan, et al., Oncogenic mutations counteract intrinsic disorder in the EGFR
kinase and promote receptor dimerization, Cell 149 (4) (2012) 860–870.
[13] M. Landau, N. Ben-Tal, Dynamic equilibrium between multiple active and inactive
conformations explains regulation and oncogenic mutations in ErbB receptors,
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1785 (1) (2008) 12–31.
[14] M.J. Eck, C.-H. Yun, Structural and mechanistic underpinnings of the differential
drug sensitivity of EGFR mutations in non-small cell lung cancer, Biochim.
Biophys. Acta 1804 (3) (2010) 559–566.
[15] K.D. Carey, et al., Kinetic analysis of epidermal growth factor receptor somatic
mutant proteins shows increased sensitivity to the epidermal growth factor re-
ceptor tyrosine kinase inhibitor, erlotinib, Cancer Res. 66 (16) (2006) 8163–8171.
[16] F.R. Hirsch, et al., Molecular predictors of outcome with gefitinib in a phase III
placebo-controlled study in advanced non-small-cell lung cancer, J. Clin. Oncol.
24 (31) (2006) 5034–5042.
[17] T.S. Mok, et al., Gefitinib or carboplatin–Paclitaxel in pulmonary adenocarcinoma,
N. Engl. J. Med. 361 (10) (2009) 947–957.
[18] R. Rosell, et al., Erlotinib versus standard chemotherapy as first-line treatment for
European patients with advanced EGFR mutation-positive non-small-cell lung
cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial, Lancet
Oncol. 13 (3) (2012) 239–246.
[19] H.A. Yu, et al., Analysis of tumor specimens at the time of acquired resistance to
EGFR-TKI therapy in 155 patients with EGFR-Mutant lung cancers, Clin. Cancer
Res. 19 (8) (2013) 2240–2246.
[20] C.-H. Yun, et al., The T790M mutation in EGFR kinase causes drug resistance by
increasing the affinity for ATP, Proc. Natl. Acad. Sci. U. S. A. 105 (6) (2008)
2070–2075.
[21] L.V. Sequist, et al., Neratinib, an irreversible pan-ErbB receptor tyrosine kinase
inhibitor: results of a phase II trial in patients with advanced non-small-cell lung
cancer, J. Clin. Oncol. 28 (18) (2010) 3076–3083.
[22] V.A. Miller, et al., Afatinib versus placebo for patients with advanced, metastatic
non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or
two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial, Lancet
Oncol. 13 (5) (2012) 528–538.
[23] N. Katakami, et al., LUX-Lung 4: a phase II trial of afatinib in patients with ad-
vanced non-small-cell lung cancer who progressed during prior treatment with
erlotinib, gefitinib, or both, J. Clin. Oncol. 31 (27) (2013) 3335–3341.
[24] M. Schuler, et al., Afatinib beyond progression in patients with non-small-cell lung
cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III rando-
mized LUX-Lung 5 trial, Ann. Oncol. 27 (3) (2016) 417–423.
[25] M. Ono, et al., Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung
cancer cell lines correlates with dependence on the epidermal growth factor (EGF)
receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway
for proliferation, Mol. Cancer Ther. 3 (4) (2004) 465–472.
[26] W. Zhou, et al., Novel mutant-selective EGFR kinase inhibitors against EGFR
T790M, Nature 462 (7276) (2009) 1070–1074.
[27] M.L. Sos, et al., Chemogenomic Profiling Provides Insights Into the Limited
Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M
EGFR Resistance Mutation, (2010).
[28] Y. Yosaatmadja, et al., Binding mode of the breakthrough inhibitor AZD9291 to
epidermal growth factor receptor revealed, J. Struct. Biol. 192 (3) (2015)
539–544.
[29] M. Ahn, et al., Osimertinib in patients with T790M mutation-positive, advanced
non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase
2 studies, Cancer 125 (6) (2019) 892–901.
[30] FDA, Osimertinib (TAGRISSO), (2017).
[31] J.-C. Soria, et al., Osimertinib in untreated EGFR -Mutated advanced non–small-
cell lung cancer, N. Engl. J. Med. 378 (2) (2018) 113–125.
[32] H.H. Loong, et al., Therapeutic strategies in EGFR mutant non-small cell lung
Cancer, Curr. Treat. Options Oncol. 19 (11) (2018) 58.
[33] G. Recondo, et al., Making the first move in EGFR-driven or ALK-driven NSCLC:
first-generation or next-generation TKI? Nat. Rev. Clin. Oncol. 15 (11) (2018)
694–708.
[34] Y. Kobayashi, et al., EGFR exon 18 mutations in lung Cancer: molecular predictors
of augmented sensitivity to afatinib or neratinib as compared with first- or third-
generation TKIs, Clin. Cancer Res. 21 (23) (2015).
[35] J.-Y. Wu, J.-Y. Shih, Effectiveness of tyrosine kinase inhibitors on uncommon
E709X epidermal growth factor receptor mutations in non-small-cell lung cancer,
Oncol. Ther. 9 (2016) 6137–6145.
[36] A. Russo, et al., Heterogeneous responses to epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mu-
tations: new insights and future perspectives in this complex clinical scenario, Int.
J. Mol. Sci. 20 (6) (2019) 1431.
[37] S. Kohsaka, et al., A method of high-Throughput functional evaluation of EGFR
gene variants of unknown significance in cancer, Sci. Transl. Med. 9 (416) (2017)
p. eaan6566.
[38] D.F. Heigener, et al., Afatinib in non-small cell lung Cancer Harboring uncommon
EGFR mutations pretreated with reversible EGFR inhibitors, Oncologist 20 (10)
(2015) 1167–1174.
[39] C.-H. Chiu, et al., Epidermal growth factor receptor tyrosine kinase inhibitor
treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I
mutations, J. Thorac. Oncol. 10 (5) (2015) 793–799.
[40] J. Xu, et al., EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-
small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: a real-
world study in China, Lung Cancer 96 (2016) 87–92.
[41] M. Beau-Faller, et al., Rare EGFR exon 18 and exon 20 mutations in non-small-cell
lung cancer on 10 117 patients: a multicentre observational study by the French
ERMETIC-IFCT network, Ann. Oncol. 25 (1) (2013) 126–131.
[42] M. He, et al., EGFR exon 19 insertions: a new family of sensitizing EGFR mutations
in lung adenocarcinoma, Clin. Cancer Res. 18 (6) (2012) 1790–1797.
[43] A.G. Iyevleva, et al., Lung Carcinomas With EGFR Exon 19 Insertions Are Sensitive
to Gefitinib Treatment, (2014).
[44] J. Park, et al., EGFR Exon 19 Insertions Show Good Response to Gefitinib, but
Short Time to Progression in Japanese Patients, (2014).
[45] J. Su, et al., Molecular characteristics and clinical outcomes of EGFR exon 19 indel
subtypes to EGFR TKIs in NSCLC patients, Oncotarget 8 (67) (2017)
111246–111257.
[46] H. Yasuda, et al., Structural, biochemical, and clinical characterization of epi-
dermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer,
Sci. Transl. Med. 5 (216) (2013) p. 216ra177.
[47] M.E. Arcila, et al., EGFR exon 20 insertion mutations in lung adenocarcinomas:
prevalence, molecular heterogeneity, and clinicopathologic characteristics, Mol.
Cancer Ther. 12 (2) (2013) 220–229.
[48] G.R. Oxnard, et al., Natural history and molecular characteristics of lung cancers
harboring EGFR exon 20 insertions, J. Thorac. Oncol. 8 (2) (2013) 179–184.
[49] J.P. Robichaux, et al., Mechanisms and clinical activity of an EGFR and HER2 exon
20-selective kinase inhibitor in non-small cell lung cancer, Nat. Med. 24 (5) (2018)
638–646.
[50] T. Kosaka, et al., Response heterogeneity of EGFR and HER2 exon 20 insertions to
covalent EGFR and HER2 inhibitors, Cancer Res. 77 (10) (2017) 2712–2721.
[51] P.A. Jänne, et al., Dacomitinib as first-line treatment in patients with clinically or
molecularly selected advanced non-small-cell lung cancer: a multicentre, open-
label, phase 2 trial, Lancet Oncol. 15 (13) (2014) 1433–1441.
[52] M. Yang, et al., NSCLC harboring EGFR exon-20 insertions after the regulatory C-
helix of kinase domain responds poorly to known EGFR inhibitors, Int. J. Cancer
139 (1) (2016) 171–176.
[53] N. Floc’h, et al., Anti-tumor activity of osimertinib, an irreversible mutant-selec-
tive EGFR tyrosine kinase inhibitor, in NSCLC harboring EGFR Exon 20 Insertions,
Mol. Cancer Ther. (2018) p. molcanther.0758.2017.
[54] F. Gonzalvez, et al., Abstract 2644: AP32788, a potent, selective inhibitor of EGFR
and HER2 oncogenic mutants, including exon 20 insertions, in preclinical models,
Cancer Res. 76 (14 Supplement) (2016) pp. 2644–2644.
[55] S. Hasako, et al., TAS6417, a novel EGFR inhibitor targeting exon 20 insertion
mutations, Mol. Cancer Ther. 17 (8) (2018) 1648–1658.
[56] J. Jang, et al., Discovery of a highly potent and broadly effective EGFR and HER2
exon 20 insertion mutant inhibitor, Angew. Chemie Int. Ed. 02115 (2018)
P.T. Harrison, et al. Seminars in Cancer Biology 61 (2020) 167–179
178
11629–11633.
[57] J. Naidoo, et al., Epidermal growth factor receptor exon 20 insertions in advanced
lung adenocarcinomas: Clinical outcomes and response to erlotinib, Cancer 121
(18) (2015) 3212–3220.
[58] P.J. Voon, et al., Letter to editor: EGFR Exon 20 insertion A763-Y764insFQEA and
response to erlotinib, Mol. Cancer Ther. 12 (November) (2013) 20–25.
[59] S. Vyse, P.H. Huang, Targeting EGFR exon 20 insertion mutations in non-small cell
lung cancer, Signal Transduct. Target. Ther. 4 (1) (2019) 5.
[60] K. Leventakos, et al., S768I mutation in EGFR in patients with lung Cancer, J.
Thorac. Oncol. 11 (10) (2016) 1798–1801.
[61] E. Banno, et al., ‘Sensitivities to various epidermal growth factor receptor-tyrosine
kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q
and S768I: what is the optimal epidermal growth factor receptor-tyrosine kinase
inhibitor?’, Cancer Sci. 107 (8) (2016) 1134–1140.
[62] H. Asahina, et al., ‘Non-responsiveness to gefitinib in a patient with lung adeno-
carcinoma having rare EGFR mutations S768I and V769L’, Lung Cancer 54 (3)
(2006) 419–422.
[63] L. Pallan, P. Taniere, P. Koh, Rare EGFR exon 20 S768I mutation predicts re-
sistance to targeted therapy: a report of two cases, J. Thorac. Oncol. 9 (10) (2014)
e75.
[64] K. Masago, et al., Good clinical response to gefitinib in a non-small cell lung
Cancer patient harboring a rare somatic epidermal growth factor gene point mu-
tation; codon 768 AGC & ATC in exon 20 (S768I), Jpn. J. Clin. Oncol. 40 (11)
(2010) 1105–1109.
[65] S. Kobayashi, et al., Compound EGFR mutations and response to EGFR tyrosine
kinase inhibitors, J. Thorac. Oncol. 8 (1) (2013) 45–51.
[66] M.D. Hellmann, et al., Clinical and in vivo evidence that EGFR S768I mutant lung
adenocarcinomas are sensitive to erlotinib, J. Thorac. Oncol. 9 (10) (2014)
e73–e74.
[67] M. Roengvoraphoj, et al., Epidermal growth factor receptor tyrosine kinase in-
hibitors as initial therapy for non-small cell lung cancer: focus on epidermal
growth factor receptor mutation testing and mutation-positive patients, Cancer
Treat. Rev. 39 (8) (2013) 839–850.
[68] J. Wang, et al., Clinical outcomes of EGFR kinase domain duplication to targeted
therapies in NSCLC, Int. J. Cancer 144 (11) (2019) 2677–2682.
[69] C.S. Baik, et al., ‘Durable response to tyrosine kinase inhibitor therapy in a lung
Cancer patient harboring epidermal growth factor receptor tandem kinase domain
duplication’, J. Thorac. Oncol. 10 (10) (2015) e97–e99.
[70] D.B. Costa, Kinase inhibitor-responsive genotypes in EGFR mutated lung adeno-
carcinomas: moving past common point mutations or indels into uncommon ki-
nase domain duplications and rearrangements, Transl. Lung Cancer Res. 5 (3)
(2016) 331–337.
[71] J.N. Gallant, et al., EGFR kinase domain duplication (EGFR -KDD) is a novel on-
cogenic driver in lung cancer that is clinically responsive to afatinib, Cancer
Discov. 5 (11) (2015) 1155–1163.
[72] L.V. Sequist, et al., Genotypic and histological evolution of lung cancers acquiring
resistance to EGFR inhibitors, Sci. Transl. Med. 3 (75) (2011) 75ra25.
[73] T. Kosaka, et al., Analysis of Epidermal Growth Factor Receptor Gene Mutation in
Patients With Non ^ Small Cell Lung Cancer and Acquired Resistance to Gefitinib,
(2006).
[74] J.-Y. Wu, et al., Effectiveness of tyrosine kinase inhibitors on &quot;Uncommon&
quot; epidermal growth factor receptor mutations of unknown clinical significance
in non-small cell lung Cancer, Clin. Cancer Res. 17 (11) (2011) 3812–3821.
[75] Y. Liu, et al., Screening for EGFR and KRAS mutations in non-small cell lung
carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-
based direct sequencing, Int. J. Clin. Exp. Pathol. 6 (9) (2013) 1880–1889.
[76] L. Peng, Z.-G. Song, S.-C. Jiao, Efficacy analysis of tyrosine kinase inhibitors on
rare non-small cell lung cancer patients harboring complex EGFR mutations, Sci.
Rep. 4 (1) (2015) 6104.
[77] C. Cheng, et al., EGFR exon 18 mutations in east asian patients with lung ade-
nocarcinomas: a comprehensive investigation of prevalence, clinicopathologic
characteristics and prognosis, Sci. Rep. 5 (1) (2015) 13959.
[78] J.H. Baek, et al., ‘Efficacy of EGFR tyrosine kinase inhibitors in patients with
EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon
21 L858R: a retrospective analysis in Korea’, Lung Cancer (2015).
[79] B. Zhang, et al., Complex epidermal growth factor receptor mutations and their
responses to tyrosine kinase inhibitors in previously untreated advanced lung
adenocarcinomas, Cancer 124 (11) (2018) 2399–2406.
[80] L.W.T. Cheung, et al., Naturally occurring neomorphic PIK3R1 mutations activate
the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors,
Cancer Cell 26 (4) (2014) 479–494.
[81] P.H. Huang, et al., Quantitative analysis of EGFRvIII cellular signaling networks
reveals a combinatorial therapeutic strategy for glioblastoma, Proc. Natl. Acad.
Sci. U. S. A. 104 (31) (2007) 12867–12872.
[82] G. Pines, et al., EGFRvIV: a previously uncharacterized oncogenic mutant reveals a
kinase autoinhibitory mechanism, Oncogene 29 (43) (2010) 5850–5860.
[83] L. Erdem-Eraslan, et al., Mutation specific functions of EGFR result in a mutation-
specific downstream pathway activation, Eur. J. Cancer 51 (7) (2015) 893–903.
[84] S. Vyse, A. Howitt, P.H. Huang, Exploiting synthetic lethality and network biology
to overcome EGFR inhibitor resistance in lung Cancer, J. Mol. Biol. 429 (12)
(2017) 1767–1786.
[85] P.T. Harrison, P.H. Huang, Exploiting vulnerabilities in cancer signalling networks
to combat targeted therapy resistance, Essays Biochem. (2018) p. EBC20180016.
[86] A. Estrada-Bernal, et al., ‘Abstract A157: Antitumor Activity of Tarloxotinib, a
Hypoxia-activated EGFR TKI, in Patient-derived Lung Cancer Cell Lines Harboring
EGFR Exon 20 Insertions’, in, pp. A157–A157 (2018).
[87] S.-Y. Kim, et al., Abstract 38: NSCLC patient-derived organoids to guide perso-
nalized therapy, Tumor Biol. (2019) pp. 38–38.
[88] N. Takahashi, et al., An in vitro system for evaluating molecular targeted drugs
using lung patient-derived tumor organoids, Cells 8 (5) (2019) 481.
[89] H. Borghaei, et al., Nivolumab versus Docetaxel in advanced nonsquamous
non–Small-Cell lung Cancer, N. Engl. J. Med. 373 (17) (2015) 1627–1639.
[90] L. Fehrenbacher, et al., Atezolizumab versus docetaxel for patients with previously
treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2
randomised controlled trial, Lancet 387 (10030) (2016) 1837–1846.
[91] M. Reck, et al., Pembrolizumab versus chemotherapy for PD-L1-Positive non-
small-Cell lung Cancer, N. Engl. J. Med. 375 (19) (2016) 1823–1833.
[92] A. Rittmeyer, et al., Atezolizumab versus docetaxel in patients with previously
treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre
randomised controlled trial, Lancet 389 (10066) (2017) 255–265.
[93] S.J. Antonia, et al., Overall survival with durvalumab after chemoradiotherapy in
stage III NSCLC, N. Engl. J. Med. 379 (24) (2018) 2342–2350.
[94] C.K. Lee, et al., Checkpoint inhibitors in metastatic EGFR-Mutated non–small cell
lung Cancer—a meta-Analysis, J. Thorac. Oncol. 12 (2) (2017) 403–407.
[95] H. Yoshida, et al., Nivolumab in non-small-cell lung cancer with EGFR mutation,
Ann. Oncol. 29 (3) (2018) 777–778.
[96] T. Yamada, et al., Retrospective efficacy analysis of immune checkpoint inhibitors
in patients with EGFR-mutated non-small cell lung cancer, Cancer Med. 8 (4)
(2019) 1521–1529.
[97] T. Yamada, et al., Retrospective efficacy analysis of immune checkpoint inhibitors
in patients with EGFR-mutated non-small cell lung cancer, Cancer Med. 8 (4)
(2019) 1521–1529.
[98] Y. Taniguchi, et al., Programmed death-ligand 1 expression in uncommon epi-
dermal growth factor receptor mutation-positive non-small-cell lung cancer, Ann.
Oncol. 29 (11) (2018) 2262–2263.
[99] S. Gettinger, et al., Five-year follow-up of Nivolumab in previously treated ad-
vanced non-small-Cell lung Cancer: results from the CA209-003 study, J. Clin.
Oncol. 36 (17) (2018) 1675–1684.
[100] C. Dominguez, K.-Y. Tsang, C. Palena, Short-term EGFR blockade enhances im-
mune-mediated cytotoxicity of EGFR mutant lung cancer cells: rationale for
combination therapies, Cell Death Dis. 7 (9) (2016) e2380.
[101] I. Moya-Horno, et al., Combination of immunotherapy with targeted therapies in
advanced non-small cell lung cancer (NSCLC), Ther. Adv. Med. Oncol. 10 (2018)
p. 1758834017745012.
[102] M.-J. Ahn, et al., EGFR TKI combination with immunotherapy in non-small cell
lung cancer, Expert Opin. Drug Saf. 16 (4) (2017) 465–469.
[103] V. Noronha, et al., Phase III randomized trial comparing gefitinib to gefitinib with
pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR
mutant non-small cell lung cancer (gef vs gef+C), J. Clin. Oncol. 37 (15_suppl)
(2019) 9001.
[104] L. Gandhi, et al., Pembrolizumab plus chemotherapy in metastatic non–Small-Cell
lung Cancer, N. Engl. J. Med. 378 (22) (2018) 2078–2092.
[105] M.A. Socinski, et al., Atezolizumab for First-Line Treatment of Metastatic
Nonsquamous NSCLC, N. Engl. J. Med. 378 (24) (2018) 2288–2301.
[106] H. West, et al., Atezolizumab in combination with carboplatin plus nab-paclitaxel
chemotherapy compared with chemotherapy alone as first-line treatment for
metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre,
randomised, open-label, phase 3 trial, Lancet Oncol. 20 (7) (2019) 924–937.
[107] L. Paz-Ares, et al., Pembrolizumab plus chemotherapy for squamous non–Small-
Cell lung Cancer, N. Engl. J. Med. 379 (21) (2018) 2040–2051.
[108] S. Kate, et al., Outcome of uncommon EGFR mutation positive newly diagnosed
advanced non-small cell lung cancer patients: a single center retrospective ana-
lysis, Lung Cancer (Auckl) 10 (2019) 1–10.
[109] P.A. Jänne, et al., Phase I dose-escalation study of the pan-HER inhibitor,
PF299804, in patients with advanced malignant solid tumors, Clin. Cancer Res. 17
(5) (2011) 1131–1139.
[110] P.A. Jänne, et al., Antitumor activity of TAK-788 in NSCLC with EGFR exon 20
insertions, J. Clin. Oncol. 37 (15_suppl) (2019) 9007.
[111] D. Chen, Z. Song, G. Cheng, Clinical efficacy of first-generation EGFR-TKIs in
patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mu-
tations, Onco Targets Ther. 9 (2016) 4181–4186.
[112] M.-J. Ahn, et al., An open-label, multicenter, phase II single arm trial of osi-
mertinib in non-small cell lung cancer patients with uncommon EGFR mutation
(KCSG-LU15-09), J. Clin. Oncol. 36 (15_suppl) (2018) 9050.
[113] A. Passaro, et al., Activity of EGFR TKIs in caucasian patients with NSCLC har-
boring potentially sensitive uncommon EGFR mutations, Clin. Lung Cancer 20 (2)
(2019) e186–e194.
[114] J. Park, et al., EGFR Exon 19 insertions show good response to Gefitinib, but short
time to progression in Japanese patients, J. Thorac. Oncol. 9 (2) (2014).
[115] A.G. Iyevleva, et al., Lung carcinomas with EGFR exon 19 insertions are sensitive
to gefitinib treatment, J. Thorac. Oncol. (2014) e31–e33.
P.T. Harrison, et al. Seminars in Cancer Biology 61 (2020) 167–179
179
